BetaEntity Annotation Prototype
← Back to institutions

Annotated abstract

A233 Impact of aspiration catheter inner diameter on first-pass effect: a systematic review and meta-analysis

neurintsurg · 2025-09-02 · canonical JSON source

11 visible annotations · policy: published · automated confidence ≥ 75.00%

Document resource

Introduction The First Pass Effect (FPE) refers to the complete or near-complete revascularization with a single pass of mechanical thrombectomy devices. While previous claims suggest a link between larger catheters and the effectiveness of Contact Aspiration (CA) thrombectomy, no extensive research has confirmed if larger distal inner diameter (ID) catheters achieve higher FPE rates.Aim of Study We conducted a meta-analysis to investigate the relationship between the ID of aspiration catheters and FPE rates.Method We searched PubMed, Scopus, and Web of Science to assess the impact of aspiration catheter distal ID size on FPE. The primary outcome was FPE rate, defined as Thrombolysis In Cerebral Ischemia (TICI) grades 2c-3 at first pass, and the secondary outcome was modified FPE (TICI 2b-3 in a single pass). Aspiration catheters were categorized based on distal ID: 0.060–0.069 (medium bore), 0.070–0.074 (large bore), and greater than 0.074 inches (super-large bore)Results FPE rates were 27.7% (95% CI, 15.1–45.3) for medium bore, 46.6% (95% CI, 33.7–59.9) for large, and 58.3% (95% CI, 44.8–70.7) for super-large catheters. The FPE rate was significantly higher for super-large bore catheters compared with other groups (χ² = 7.26, p = 0.03). A similar trend was observed for modified FPE rates, which were 51.1% (95% CI, 45.3–56.8) for medium bore, 60.0% (95% CI, 52.8–66.8) for large bore, and 80% (95% CI, 56.3–94.2) for super-large bore catheters (χ² = 8.14, p = 0.03).Abstract A233 Table 1Conclusion Our analysis indicates that larger CA catheters are correlated with higher FPE rates.Conflict of Interest Yes JC received research grant from Medtronic, Phenox and Microvention; and received honoraria for lectures from Balt. DFK received research support from Cerenovus, Sensome, Neurogami Medical, Insera Therapeutics, Medtronic, Microvention, Balt, Monarch Biosciences, Brainomix, MiVi, Stryker and NIH; royalties from Medtronic; is on the DSMB of NoNO Inc and Vesalio; is a stockholder Nested Knowledge, Superior Medical Experts, Marblehead Medical, and Conway Medical.